Gout and Hyperuricaemia Diagnosis
Gout and Hyperuricaemia Diagnosis
Two things make gout unusual among the conditions patients arrive with: the blood test that names it is not the test that diagnoses it, and the reading taken at the moment a patient is most worried is the least useful one they will have. This page sets out what the urate level does and does not establish, how crystals are found, what imaging adds, how the source of the urate is identified, and what a complete assessment contains.
What the urate level does and does not establish
Serum urate is the number that defines hyperuricaemia and the number that treatment is aimed at. It is not the number that makes the diagnosis, and understanding why saves both false alarms and missed cases.
The threshold matters first. Urate comes out of solution above its saturation point — roughly 404 μmol/l (6.8 mg/dl) — and hyperuricaemia is conventionally defined as a level above about 420 μmol/l (7.0 mg/dl) in men and 360 μmol/l (6.0 mg/dl) in women. Those thresholds describe a concentration, not a disease. Most people above them never form a crystal, and treating the number in someone who has never had an attack is a decision that has to be weighed rather than assumed.
The second thing is the one that catches people out in both directions. During an acute attack, urate falls. Inflammation changes how the kidney handles it, and the level can drop into the normal range for several weeks afterwards. A reading taken in the emergency department during a flare is therefore the least informative one a patient will have, and a normal result at that moment never excludes gout. The measurement worth acting on is a repeat taken once the joint has been quiet for a few weeks.
The two numbers also answer different questions, which is why both are needed at different times. The level says whether there is a concentration to treat and, later, whether treatment has reached its target. The crystals say whether the concentration has actually produced the disease. A treatment decision made on the first without the second is how people are medicated for years for a condition they do not have — and how others are told they do not have gout because a test was taken on the wrong day.
Joint fluid: the test that settles it
Aspirating the inflamed joint and examining the fluid under polarised light microscopy is the reference standard. It is a short procedure under local anaesthetic, and it answers two questions at once — one of which is the more important of the two.
The first question is whether crystals are present. Monosodium urate crystals are needle-shaped and negatively birefringent: under polarised light with a compensator they appear yellow when aligned parallel to it and blue when perpendicular. Their presence in fluid from an inflamed joint is the diagnosis of gout, and it remains the diagnosis even when the blood level is normal.
The second question is whether there is infection, and this is the one that changes management on the day. Septic arthritis produces the same hot, red, exquisitely tender joint, it destroys a joint within days rather than years, and it is treated with antibiotics and drainage rather than with anti-inflammatories. No blood test separates the two reliably. Where there is fever, a prosthetic joint, a recent injection into that joint, or immunosuppression, aspiration is not a refinement — it is the test that decides between an anti-inflammatory and an antibiotic.
What fluid also gives is the answer to the question most patients have not thought to ask: which crystals. Calcium pyrophosphate crystals — the cause of pseudo-gout — look different under the same microscope, favour the knee and wrist, and have a different long-term management. Two conditions that look identical from the doorway are separated by a slide.
What imaging adds
Imaging does not replace microscopy where a joint can be aspirated, but it does three things that fluid cannot, and it is often how the diagnosis is reached in practice.
| Modality | What it shows | When it earns its place |
|---|---|---|
| Ultrasound | Crystal deposition on the cartilage surface — the double contour sign — and the tophus within soft tissue | Where aspiration is not possible or is declined, and to demonstrate deposits in a joint that is not currently inflamed |
| Dual-energy CT | Urate distinguished from surrounding tissue by its composition, and colour-coded | Where the diagnosis is unclear, where the joint is deep or inaccessible, or where tophus burden needs measuring |
| Plain X-ray | Joint erosions with overhanging edges, and soft-tissue swelling | Late findings. Normal early, which is why a normal X-ray never excludes the diagnosis |
| Ultrasound or CT of the urinary tract | Radiolucent stones and obstruction, which urate stones often are on plain film | Where loin pain, blood in the urine or reduced output accompanies gout |
One caution belongs with the table. A normal X-ray is the commonest false reassurance in this disease: erosions take years, and their absence says nothing about whether crystals are present. The investigations that change management early are the fluid and the ultrasound, not the radiograph.
Establishing why your level is high
Once gout is confirmed, the next question is the source of the urate, and the answer is not always the obvious one. Production and clearance can each be at fault, they are treated differently, and in a substantial share of patients the real driver is a medicine prescribed years earlier for something else.
| Test | What it is looking for | When it earns its place |
|---|---|---|
| Kidney function and urine urate | Whether the kidney is clearing enough urate, and how much is being produced | Nearly always. Reduced clearance is the commonest mechanism, and a 24-hour urine collection separates under-excretion from overproduction |
| Medicines review | Diuretics, low-dose aspirin, ciclosporin, pyrazinamide, ethambutol and others that raise urate | Always, and before adding a medicine. Substituting one drug can remove the need for another |
| Metabolic panel | Blood pressure, glucose, lipids, weight — the pattern gout travels with | Always. These are treated in the same plan, and they carry more long-term risk than the joint does |
| Blood count and inflammatory markers | A myeloproliferative or psoriatic condition, or inflammation that is not crystal-driven | Where gout presents young, where attacks are atypical, or where the picture does not fit |
| Stone analysis | The composition of a stone already passed | Where stones are part of the picture; urate stones are radiolucent and are managed differently from calcium ones |
On uricase specifically: the reason humans are susceptible to this at all is that we do not have the enzyme that most other mammals use to break urate down further. That is the whole of the evolutionary explanation, and it is why diet alone is rarely sufficient — the clearance side is doing most of the work in most people.
What a complete assessment contains
For international patients the assessment is built around records, because much of it already exists in any well-kept file. What we ask for is the urate results with dates, a description of the attacks and which joints were involved, the kidney function tests, any imaging or joint fluid reports, the full medicines list including anything bought over the counter, and the history of the conditions that travel with gout — hypertension, diabetes, kidney disease, psoriasis, and any blood disorder.
The written opinion that comes back covers four things: whether the pattern is gout or something else, what is most likely driving the urate level, which missing tests would change the treatment, and whether assessment here would add anything to the care already being received. Where the answer is that the diagnosis is already clear and well managed, that is what the letter says. The review is free and it precedes any discussion of travel or payment, which is the ordering patients tell us matters most.